Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
44 studies found for:    Open Studies | "Rhabdomyosarcoma"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Proton RT for the Treatment of Pediatric Rhabdomyosarcoma
Condition: Rhabdomyosarcoma
Intervention: Radiation: Proton Beam Radiation
2 Recruiting Treatment of Rhabdomyosarcoma With Chemotherapy, Radiation Therapy (Proton Beam), and Surgery
Condition: Rhabdomyosarcoma
Interventions: Drug: Vincristine;   Drug: Dactinomycin;   Drug: Cyclophosphamide;   Procedure: Surgical Resection;   Procedure: Radiation;   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Myeloid Growth Factor;   Procedure: Lymph Node Sampling;   Drug: Irinotecan;   Drug: Ifosfamide;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Drug: Doxorubicin;   Drug: Dexrazoxane
3 Recruiting A Study Comparing Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
Conditions: Rhabdomyosarcoma;   Melanoma
Interventions: Drug: Tc99m tilmanocept;   Drug: Vital Blue Dye
4 Recruiting Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors
Conditions: Ewing Sarcoma;   Rhabdomyosarcoma;   Wilms Tumor
Intervention: Radiation: Stereotactic Body Radiotherapy (SBRT)
5 Recruiting Phase I Trial of Afatinib in Pediatric Tumours
Conditions: Neuroectodermal Tumors;   Rhabdomyosarcoma
Intervention: Drug: afatinib
6 Recruiting Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Intervention: Drug: trofosfamide, idarubicin, etoposide
7 Recruiting Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Conditions: Pleuropulmonary Blastoma;   Recurrent Malignant Peripheral Nerve Sheath Tumor;   Recurrent Neuroblastoma;   Recurrent Rhabdomyosarcoma;   Recurrent Synovial Sarcoma;   Wilms Tumor
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Lorvotuzumab Mertansine;   Other: Pharmacological Study
8 Recruiting A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
Condition: Relapsed or Refractory Medulloblastoma (MB) [Part A: Also Include Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)]
Interventions: Drug: TB-403 20mg/kg;   Drug: TB-403 50mg/kg;   Drug: TB-403 100mg/kg;   Drug: TB-403 ≤175mg/kg
9 Recruiting Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Conditions: Adult Rhabdomyosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Chordoma;   Desmoid Tumor;   Metastatic Childhood Soft Tissue Sarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Previously Untreated Childhood Rhabdomyosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Stage I Adult Soft Tissue Sarcoma;   Stage II Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
10 Recruiting Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas
Conditions: Ewing Sarcoma;   Osteosarcoma;   Rhabdomyosarcoma
Intervention: Biological: Expanded , Activated NK cells
11 Recruiting Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
Conditions: Osteosarcoma;   Ewing Sarcoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma
Interventions: Drug: nab-Paclitaxel;   Drug: Gemcitabine
12 Recruiting Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Conditions: Acute Lymphoblastic Leukemia;   Brain Neoplasm;   Hodgkin Lymphoma;   Rhabdomyosarcoma
Interventions: Procedure: Assessment of Therapy Complications;   Other: Questionnaire Administration
13 Recruiting To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Conditions: Neuroblastoma;;   Rhabdomyosarcoma;;   Ewing's Sarcoma;;   Ewing's Tumor;;   Sarcoma, Ewing's;;   Sarcomas, Epitheliod;;   Sarcoma, Soft Tissue;;   Sarcoma, Spindle Cell;;   Melanoma;;   Malignant Melanoma;;   Clinical Oncology;;   Oncology, Medical;;   Pediatrics, Osteosarcoma;;   Osteogenic Sarcoma;;   Osteosarcoma Tumor;;   Sarcoma, Osteogenic;;   Tumors;;   Cancer;;   Neoplasia;;   Neoplasm;;   Histiocytoma;;   Fibrosarcoma;;   Dermatofibrosarcoma
Intervention: Drug: nab-paclitaxel
14 Recruiting Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors
Conditions: Recurrent or Refractory Solid Tumors;   Ewing Sarcoma;   Rhabdomyosarcoma;   Neuroblastoma;   Osteosarcoma
Intervention: Drug: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
15 Recruiting Advanced MR Imaging in Sarcoma Patients
Condition: Sarcoma
Intervention:
16 Recruiting Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors
Conditions: Ewing Sarcoma;   Neuroblastoma;   Rhabdomyosarcoma;   Osteosarcoma;   CNS Tumors
Interventions: Procedure: Allogeneic HCT;   Drug: Donor NK Cell Infusion
17 Not yet recruiting HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors
Conditions: Rhabdomyosarcoma;   Neuroblastoma;   Sarcoma;   Sarcoma, Ewing;   Osteosarcoma
Interventions: Drug: Doxorubicin HCl liposomal injection;   Device: Philips Sonalleve MR-HIFU Hyperthermia
18 Recruiting Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas
Conditions: Sarcoma, Bone;   Sarcoma, Soft Tissue;   Osteosarcoma;   Sarcoma, Ewing;   Rhabdomyosarcoma;   Non-rhabdomyosarcoma Soft-tissue Sarcoma
Intervention: Procedure: Diffusion Weighted Magnetic Resonance Imaging
19 Not yet recruiting Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Conditions: Adrenal Cortex Carcinoma;   Adult Alveolar Soft Part Sarcoma;   Adult Clear Cell Sarcoma of Soft Parts;   Adult Hepatocellular Carcinoma;   Adult Rhabdomyosarcoma;   Adult Soft Tissue Sarcoma;   Childhood Alveolar Soft Part Sarcoma;   Childhood Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Childhood Hepatocellular Carcinoma;   Childhood Rhabdomyosarcoma;   Childhood Soft Tissue Sarcoma;   Childhood Solid Neoplasm;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adult Hepatocellular Carcinoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Hepatocellular Carcinoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Solid Neoplasm;   Renal Cell Carcinoma;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
20 Recruiting CREATE: Cross-tumoral Phase 2 With Crizotinib
Conditions: Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma;   Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor;   Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1;   Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma;   Locally Advanced and/or Metastatic Clear Cell Sarcoma;   Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma
Intervention: Drug: Crizotinib (PF-02341066)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.